An Alberta-based research group plans to launch a blood test that could improve the specificity of prostate cancer diagnosis and reduce the number of biopsies.
The firm will encounter stiff competition, particularly from BioMérieux and Luminex, but there are untapped opportunities for adoption, according to industry analysts.
Market growth is providing opportunities for emerging diagnostic companies and a range of options for clinicians, included PCR and protein tests.
The firm has already received CE marking for its nanofluidic point-of-care assay, which could provide rapid identification of sepsis in patients.
The test could help stem the infection's advance in regions where the kissing bug is prevalent, and enable screening in other affected countries.
The test, which went off the market when its original seller closed shop, uses an ultracentrifuge and spectrophotometer to measure cholesterol and triglycerides.
Roche's Bluetooth-enabled meter gives patients the option to bypass frequent trips to the clinic in favor of doing anticoagulation testing at home.
The company's test measures epigenetic alteration of two genes using Qiagen PCR methods, in order to detect signs of recurrence in colorectal cancer patients post-surgery.
The British molecular diagnostics company plans to make its array-based test for early-stage Alzheimer's disease available in the US by year end.
The company has aspirations for a combined molecular/immunoassay platform, but plans to go to market with a 22-target real-time PCR-enabled syndromic panel.